5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer

被引:0
|
作者
Aditi Patra
Moonmoon Deb
Rajvir Dahiya
Samir Kumar Patra
机构
[1] Bidhan Chandra Krishi Viswaidyalaya,Department of Animal Science
[2] National Institute of Technology,Epigenetics and Cancer Research Laboratory, Department of Life Science
[3] University of California at San Francisco and VA Medical Center,Department of Urology
来源
Clinical Epigenetics | 2011年 / 2卷
关键词
Epigenome; CpG hypermethylation; DNMT; 5-Aza-2′-deoxycytidine; Apoptosis; Prostate cancer;
D O I
暂无
中图分类号
学科分类号
摘要
While studying on epigenetic regulatory mechanisms (DNA methylation at C-5 of –CpG– cytosine and demethylation of methylated DNA) of certain genes (FAS, CLU, E-cadh, CD44, and Cav-1) associated with prostate cancer development and its better management, we noticed that the used in vivo dose of 5-aza-2′-deoxycytidine (5.0 to 10.0 nM, sufficient to inhibit DNA methyltransferase activity in vitro) helped in the transcription of various genes with known (steroid receptors, AR and ER; ER variants, CD44, CDH1, BRCA1, TGFβR1, MMP3, MMP9, and UPA) and unknown (DAZ and Y-chromosome specific) proteins and the respective cells remained healthy in culture. At a moderate dose (20 to 200 nM) of the inhibitor, cells remain growth arrested. Upon subsequent challenge with increased dose (0.5 to 5.0 μM) of the inhibitor, we observed that the cellular morphology was changing and led to death of the cells with progress of time. Analyses of DNA and anti-, pro-, and apoptotic factors of the affected cells revealed that the molecular events that went on are characteristics of programmed cell death (apoptosis).
引用
收藏
页码:339 / 348
页数:9
相关论文
共 50 条
  • [1] 5-Aza-2'-deoxycytidine stress response and apoptosis in prostate cancer
    Patra, Aditi
    Deb, Moonmoon
    Dahiya, Rajvir
    Patra, Samir Kumar
    CLINICAL EPIGENETICS, 2011, 2 : 339 - 348
  • [2] 5-AZA-2′-DEOXYCYTIDINE IS A POTENTIAL INHIBITOR OF HUMAN PROSTATE CANCER INVASION
    Chen, Lin
    Zhang, Qiang
    Helfand, Brian
    Sharma, Vidit
    Qin, Weijun
    Brendler, Charles
    Zhu, Lihua
    Kundu, Shilajit D.
    Jiang, Thomas
    Zhang, Weipeng
    Lee, Bob
    Randall-London, Sherin
    Jovanovic, Borko
    Yang, Ximing J.
    Kozlowski, James
    Kuzel, Timothy Michael
    Guo, Yinglu
    Lee, Chung
    JOURNAL OF UROLOGY, 2011, 185 (04): : E168 - E168
  • [3] 5-AZA-2′-deoxycytidine in cancer immunotherapy:: A mouse to man story -: Response
    Guo, Z. Sheng
    Restifo, Nicholas P.
    Schrump, David S.
    CANCER RESEARCH, 2007, 67 (06) : 2901 - 2902
  • [4] Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine)
    Momparler, RL
    SEMINARS IN ONCOLOGY, 2005, 32 (05) : 443 - 451
  • [5] KINETICS OF PHOSPHORYLATION OF 5-AZA-2'-DEOXYCYTIDINE BY DEOXYCYTIDINE KINASE
    MOMPARLER, RL
    DERSE, D
    BIOCHEMICAL PHARMACOLOGY, 1979, 28 (08) : 1443 - 1444
  • [6] Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)
    Momparler, RL
    SEMINARS IN HEMATOLOGY, 2005, 42 (03) : S9 - S16
  • [7] AN ANALYTICAL STUDY OF 5-AZA-2'-DEOXYCYTIDINE
    TOMANKOVA, H
    ZYKA, J
    PILECKOVA, Z
    MICROCHEMICAL JOURNAL, 1984, 29 (03) : 333 - 340
  • [8] 5-aza-2′-deoxycytidine in myelodysplasia.
    Kell, WJ
    Burnett, AK
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 64 - 64
  • [9] 5-AZA-2'-DEOXYCYTIDINE IN ADVANCED OR RECURRENT CANCER OF THE UTERINE CERVIX
    VERMORKEN, JB
    TUMOLO, S
    ROOZENDAAL, KJ
    GUASTALLA, JP
    SPLINTER, TAW
    RENARD, J
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (02) : 216 - 217
  • [10] Proteomic Analysis of Liver Cancer Cells Treated With 5-Aza-2′-Deoxycytidine (AZA)
    Bai, Shujun
    Tong, Aiping
    Lau, Quek Choon
    Liu, Rui
    Tang, Minghai
    Chen, Lijuan
    Huang, Canhua
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (01) : 22 - 34